In non-severe COVID-19 patients, an initial therapeutic strategy with heparin increases the chance of survival after discharge and reduces the need for respiratory and cardiovascular support compared against usual thromboprophylaxis doses. These data have been welcomed by a medical community eager to receive good news in terms of effective strategies to combat an already existing…